BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. (BCTX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BCTX · as of Jun 8, 2026
Key Statistics
Explore BriaCell Therapeutics Corp. Data
bctx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
Competitors & Peers
bctx competitorsBCTX
ALLR
ASBP
CRIS
CTXR
ENTOStock Performance
Full HistoryAbout BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is …
what is briacell therapeutics corp. · bctx stock overview · briacell therapeutics corp. company profile · who is briacell therapeutics corp. ceo · bctx NASDAQ · briacell therapeutics corp. headquarters · briacell therapeutics corp. business segments
About Stock Overview & Key Data
BriaCell Therapeutics Corp. (BCTX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 14, 2012. As of the latest trading session, BCTX stock price is $3.10, with a market capitalization of $5.8M. The stock has returned -91.12% over the past 12 months and -56.54% year-to-date.
According to 1 Wall Street analysts, the consensus rating for BriaCell Therapeutics Corp. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, BriaCell Therapeutics Corp. reported revenue of — and net income of -$36.5M. For detailed data — including BriaCell Therapeutics Corp. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, BriaCell Therapeutics Corp. (BCTX) stock price is $3.10. The stock is traded on NASDAQ under the ticker symbol BCTX. The 52-week range is $2.98 – $36.00.